News >

Blood Test May Predict Palbociclib Response Earlier in Breast Cancer

Jason Harris
Published: Friday, Mar 02, 2018

Nicholas Turner, MD, PhD

Nicholas Turner, MD, PhD
A blood test that detects early changes in circulating tumor DNA (ctDNA) may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to the CDK4/6 inhibitor palbociclib (Ibrance), according to findings published in Nature Communications.

In the United States, palbociclib is approved by the FDA for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or fulvestrant in women with disease progression following endocrine therapy.
O’Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer [published online March 1, 2018]. Nat Commun. doi:10.1038/s41467-018-03215-x.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication